TNF involvement and anti-TNF therapy of reactive and unclassified arthritis

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S130-4.

Abstract

A growing body of evidence shows that tumor necrosis factor (TNF) alpha, a pro-inflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA), is also involved in the pathogenesis of reactive and unclassified arthritis. Elevated levels of TNF-alpha and other pro-inflammatory cytokines are seen in these inflammatory arthropathies. The clinical effect on a potential underlying infection is not known, but several studies have suggested at least short-term effectiveness and safety of anti-TNF-alpha therapy in reactive and unclassified arthritis.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis / drug therapy*
  • Arthritis / physiopathology*
  • Arthritis, Reactive / drug therapy*
  • Arthritis, Reactive / physiopathology*
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunologic Factors / therapeutic use
  • Infliximab
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept